JAK1 and liver dysplastic nodule: For example, baricitinib acts as a selective inhibitor of JAK1 and JAK2, and in a clinical trial evaluating type 2 diabetic adults at high risk of progressive DN, baricitinib was found to significantly reduce albuminuria, thereby improving DN (13).